Calls Now Open
2022 ADDF-Harrington and 2023 Harrington UK Rare Disease Programs
Bruce Daugherty, PhD, MBA is an experienced pharmaceutical and biotechnology leader with depth in multiple therapeutic areas, including immunology and inflammation, antiviral, cardiovascular and CNS. He has worked in both large pharma and start-up environments and on projects involving collaborators in academia and in CROs.
VP and Acting CSO, Targazyme
Former CSO, Tonix Pharmaceuticals
Former Senior Research Fellow, Merck and Co.